The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | CAR T-cells for lymphoma: data from ASH 2017
CAR T-cells are a particularly exciting therapeutic area, which was widely covered at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. In this video, Graham Collins, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses his highlights of the CAR T-cell data presented at the meeting in regards to lymphoma. Dr Collins covers the promising longer-term results being seen now in overall and complete response rates, the main caveat to the data and the questions that we can expect to be answered by further studies.
